Premature ejaculation describes the phenomenon which occurs when ejaculation happens persistently sooner than a man or his partner would like during sexual activity. About 30% of men are affected but possibly up to 75% in some reviews. It is considered to be the most common male sexual disorder.

There are several different definitions of premature ejaculation. It has been defined simply as an inability to exert voluntary control over the ejaculatory reflex or as the condition where a man reaches orgasm and ejaculates before he desires to do so.

Overall, premature ejaculation is primarily psychological in nature. However, the precise cause of premature ejaculation remains largely undetermined. Several contributing risk factors, both biological and psychological, have been identified: Biological factors (abnormal levels of the brain neurotransmitter serotonin, abnormal hormonal levels, e.g., LH, prolactin, and TSH, inflammation and/or infection of the prostate or urethra, erectile dysfunction (ED), genetic predisposition, hyperthyroidism, neuropathy, alcoholism, diabetes, sleep deprivation - Psychological factors: Depression, anxiety, stress, guilt, narcissism, performance anxiety etc.

When, in the early 2010s, Menarini Group entered the Andrology Therapeutic Area acquiring the rights for the first European approved oral treatment for Premature Ejaculation (PE), the Company unveiled for the very first time the burden of one the most common male sexual diseases.

"Αυτές οι πληροφορίες προορίζονται για γενική πληροφόρηση και ενημέρωση του κοινού και σε καμία περίπτωση δεν μπορούν να υποκαταστήσουν τη συμβουλή ιατρού ή άλλου αρμόδιου επαγγελματία υγείας"

Erectile dysfunction is defined as the persistent inability to achieve or maintain penile erection sufficient for satisfactory sexual performance. The Massachusetts Male Aging Study surveye 1,709 men aged 40–70 years between 1987 and 1989 and found there was a total prevalence of erectile dysfunction of 52 percent. It was estimated that, in 1995, over 152 million men worldwide experienced ED. For 2025, the prevalence of ED is predicted to be approximately 322 million worldwide.

Direct risk factors for erectile dysfunction may include the following: prostate problems, type 2 diabetes, hypertension (high blood pressure), vascular disease and vascular surgery, high levels of blood cholesterol, low levels of HDL (high-density lipoprotein), chronic sleep disorders (obstructive sleep apnea, insomnia), drugs, neurogenic disorders, priapism (inflammation of the penis), depression, alcohol use, inadequate interpersonal relationships, smoking etc.

Menarini Group in order to offer to both physicians and patients a full therapeutic armamentarium in Andrology, starting from 2014, has been committed in Erectile Dysfunction (ED) treatment.

"Αυτές οι πληροφορίες προορίζονται για γενική πληροφόρηση και ενημέρωση του κοινού και σε καμία περίπτωση δεν μπορούν να υποκαταστήσουν τη συμβουλή ιατρού ή άλλου αρμόδιου επαγγελματία υγείας"